

| | | | |
|---|--|--------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney Docket No. 06275-0150003 | Application No. 10/010,283 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) | | Applicant Carl-Axel Bauer et al. | |
| | | Filing Date November 13, 2001 | Group Art Unit 1617 |
| (37 CFR §1.98(b)) | | | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|---|
| Examiner Initial | Desig. ID | Document |
| | 1 | Notice of Opposition, filed by Ranbaxy Laboratories Limited, opposing the grant of Patent Application No. 190791 by Intellectual Property India (India Patent Office), dated June 1, 2006 (21 pages). |
| | 2 | Reply statement before the Opposition Board, Patent Office, Delhi; submitted on behalf of AstraZeneca, dated July 27, 2006 (6 pages). |
| | 3 | Affidavit of Jan William Trofast, before the Opposition Board, Patent Office, Delhi; submitted on behalf of AstraZeneca, dated September 13, 2006 (7 pages). |
| | 4 | Opponent Response in Opposition to Patent No. 19071, submitted by Lakshmi Kumaran & Sridharan, dated November 3, 2006 (6 pages). |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |